Necitumumab
Wikipedia on Answers.com:
Top
Necitumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | EGFR |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 906805-06-9  |
| ATC code | None |
| UNII | 2BT4C47RUI  |
| Chemical data | |
| Formula | C6436H9958N1702O2020S42 |
| Mol. mass | 144.84 kDa |
 (what is this?) (verify) |
|
Necitumumab (proposed INN) is a monoclonal antibody and an antineoplastic. It binds to the epidermal growth factor receptor (EGFR).[1] As of October 2009[update], two Phase III clinical trials are planned to investigate its effects on non-small cell lung carcinoma.[2][3]
References
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ^ ClinicalTrials.gov NCT00981058 Squamous Non-Small Cell Lung Cancer (NSCLC) Treatment With the Inhibitor of Epidermal Growth Factor Receptor (EGFR) (SQUIRE)
- ^ ClinicalTrials.gov NCT00982111 NonSquamous Non-Small Cell Lung Cancer Treatment With the Inhibitor of Epidermal Growth Factor Receptor (INSPIRE)
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
Related Videos:
Top
Necitumumab
Post a question - any question - to the WikiAnswers community:
Copyrights:
Wikipedia on Answers.com
This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Necitumumab.
Read more